title: Activation of Nrf2 pathways correlates with resistance of NSCLC cell lines to CBP501 in vitro.
abstract: CBP501 is an anticancer drug candidate that was investigated in two randomized phase II clinical trials for patients with nonsquamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). CBP501 has been shown to have two mechanisms of action, namely calmodulin modulation and G2 checkpoint abrogation. Here, we searched for a biomarker to predict sensitivity to CBP501. Twenty-eight NSCLC cell lines were classified into two subgroups, CBP501-sensitive and -insensitive, by quantitatively analyzing the cis-diamminedichloro-platinum (II) (CDDP)-enhancing activity of CBP501 through treatments with short-term (1 hour) coexposure to CDDP and CBP501 or to either alone. Microarray analysis was performed on these cell lines to identify gene expression patterns that correlated with CBP501 sensitivity. We found that multiple nuclear factor erythroid-2-related factor 2 (Nrf2) target genes showed high expression in CBP501-insensitive cell lines. Western blot and immunocytochemical analysis for Nrf2 in NSCLC cell lines also indicated higher protein level in CBP501-insensitive cell lines. Moreover, CBP501 sensitivity is modulated by silencing or sulforaphane-induced overexpression of Nrf2. These results indicate that Nrf2 transcription factor is a potential candidate as a biomarker for resistance to CBP501. This study might help to identify those subpopulations of patients who would respond well to the CBP501 and CDDP combination treatment of NSCLC.
authors: CanBas Co., Ltd., Numazu, Japan.
authors: Naoki
authors: N
authors: Mine
authors: CanBas Co., Ltd., Numazu, Japan.
authors: Sayaka
authors: S
authors: Yamamoto
authors: Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
authors: Donald W
authors: DW
authors: Kufe
authors: Translational Genomics Research Institute (TGen), Phoenix, Arizona.
authors: Daniel D
authors: DD
authors: Von Hoff
authors: CanBas Co., Ltd., Numazu, Japan. takumi@canbas.co.jp.
authors: Takumi
authors: T
authors: Kawabe
mesh_terms: D014408:Biomarkers, Tumor / Q000737:chemistry; D002147:Calmodulin / Q000737:chemistry; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism*; D002453:Cell Cycle; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm; D016195:G2 Phase; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D016086:Lentivirus / Q000378:metabolism; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D008856:Microscopy, Fluorescence; D051267:NF-E2-Related Factor 2 / Q000378:metabolism*; D020411:Oligonucleotide Array Sequence Analysis; D010446:Peptide Fragments / Q000737:chemistry*; D012333:RNA, Messenger / Q000378:metabolism; D034741:RNA, Small Interfering / Q000378:metabolism; D020687:cdc25 Phosphatases / Q000737:chemistry*
chemical_list: D014408:Biomarkers, Tumor; D002147:Calmodulin; C517976:Cdc25C phosphatase (211-221); D051267:NF-E2-Related Factor 2; C495635:NFE2L2 protein, human; D010446:Peptide Fragments; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D020687:cdc25 Phosphatases